The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic factors for overall survival in patients with advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: A post-hoc analysis of JCOG1213.
 
Hidekazu Hirano
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Fujifilm; Novartis; Taiho Pharmaceutical; Teijin Pharma
Research Funding - BeiGene (Inst)
 
Kenro Hirata
Honoraria - Bristol-Myers Squibb Company; Eli Lilly Japan K.K.; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Ono Pharmaceutical; Taiho Pharmaceutical
 
Yoshitaka Honma
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Lilly; Merck Serono; MSD; Novartis; Nutrisystem; Ono Pharmaceutical; Teijin Pharma; Teijin Pharma
Consulting or Advisory Role - Eisai; Janssen; Rakuten Medical
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Lilly; Merck Serono; MSD; Novartis; Nutrisystem; Ono Pharmaceutical; Teijin Pharma
Research Funding - Adlai Nortye; Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma; GlaxoSmithKline; Janssen; Maruho; Merck Serono; MSD; Novartis; Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical
 
Chigusa Morizane
Honoraria - AstraZeneca; Eisai; Incyte Japan; MSD K.K.; Novartis; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck; MSD K.K.; SERVIER; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo RD Novare; Eisai (Inst); Hitachi (Inst); J-Pharma (Inst); Merck (Inst); ONO PHARMACEUTICAL (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Nozomu Machida
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck KGaA; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - ALX Oncology (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Takuji Okusaka
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte; Johnson & Johnson/MedTech; Myriad Genetics; Nihon Servier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Dainippon Sumitomo Pharma; Eisai; FUJIFILM Toyama Chemistry; Nihon Servier
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience; Eisai (Inst); Incyte; Syneos Health/Immunocore (Inst); Sysmex (Inst)
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Daiichi-Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Takeda (Inst)
 
Shigeki Sekine
Honoraria - MSD (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst)
 
Nobuyoshi Hiraoka
No Relationships to Disclose
 
Gakuto Ogawa
No Relationships to Disclose
 
Yusuke Sano
No Relationships to Disclose
 
Yuichi Shibuya
No Relationships to Disclose
 
Masanobu Takahashi
Speakers' Bureau - Bristol-Myers Squibb Japan; Daiichi Sankyo; Ono Pharmaceutical; Taiho Pharmaceutical
 
Nao Fujimori
No Relationships to Disclose
 
Motoo Nomura
Honoraria - Bristol-MyersSquibbK.K.; MSD; ONOPHARMACEUTICALCO.,LTD.
 
Yuichiro Doki
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Chugai Pharma; Daiichi Sankyo; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Makoto Ueno
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Incyte; J-pharma; MSD; Mylan; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim; Novocure
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); J-pharma (Inst); JPH Clinical Development (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Takaki Yoshikawa
Honoraria - Astellas Pharma; AstraZeneca; BMS; Chugai Pharma; Daiichi Sankyo; EA Pharma; Intuitive Surgical; Japan Blood Products Organization; Johnson & Johnson/Janssen; Lilly; Medtronic; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - MSD Oncology; TERUMO
Research Funding - Lilly
 
Hiroya Takeuchi
Honoraria - Abbott Japan; Bristol-Myers Squibb Japan; Daiichi Sankyo/Astra Zeneca; EA Pharma; Hisamitsu Pharmaceutical; Intuitive Surgical; Johnson & Johnson/MedTech; Kaken Pharmaceutical; Medicon; Medtronic; Miyarisan pharmaceutical; MSD K.K; Nichiiko K.K.; Ono Pharmaceutical; Otsuka; Otsuka; Taiho Pharmaceutical; Tsumura & Co.
Research Funding - Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Johnson & Johnson/MedTech; Kaken Pharmaceutical; Kyowa Hakko Kirin K. K.; Lilly Japan; Otsuka; Taiho Pharmaceutical